The 2026 guidelines bring clinically meaningful updates to specific LDL-C targets, risk calculation, earlier intervention strategies, and expanded use of ApoB.
John Bucheit, PharmD, BCACP
Advertisement
Articles by John Bucheit, PharmD, BCACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
5